{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:42:15Z","timestamp":1780605735096,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,17]]},"DOI":"10.7759\/cureus.86235","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:45:57Z","timestamp":1750189557000},"source":"Crossref","is-referenced-by-count":1,"title":["Multivessel Coronary Artery Disease in a Patient Treated With Tofacitinib: A Case Report"],"prefix":"10.7759","author":[{"given":"Wongelawit","family":"Zerihun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joud","family":"Fahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhue","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fana","family":"Cisse-Diouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib). (2022). Accessed. 01\/20\/2025: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/initial-safety-trial-results-find-increased-risk-serious-heart-rel...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19895492","article-title":"Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Xie W","year":"2019","unstructured":"Xie W, Xiao S, Huang Y, Sun X, Zhang Z. Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2019, 11:1759720X19895492. 10.1177\/1759720X19895492","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023, 82:3-18. 10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar F","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022, 81:798-804. 10.1136\/annrheumdis-2021-221915","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg SR","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al.. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022, 386:316-26. 10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0628-9","article-title":"The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review","volume":"41","author":"Nurmohamed M","year":"2018","unstructured":"Nurmohamed M, Choy E, Lula S, Kola B, DeMasi R, Accossato P. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Saf. 2018, 41:473-88. 10.1007\/s40264-017-0628-9","journal-title":"Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1226760","article-title":"Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis","volume":"10","author":"Kacs\u00e1ndi D","year":"2023","unstructured":"Kacs\u00e1ndi D, Fagyas M, Horv\u00e1th \u00c1, et al.. Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis. Front Med (Lausanne). 2023, 10:1226760. 10.3389\/fmed.2023.1226760","journal-title":"Front Med (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00177-4","article-title":"Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis","volume":"6","author":"Reed GW","year":"2019","unstructured":"Reed GW, Gerber RA, Shan Y, et al.. Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. Rheumatol Ther. 2019, 6:573-86. 10.1007\/s40744-019-00177-4","journal-title":"Rheumatol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221149965","article-title":"Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib","volume":"15","author":"Kristensen LE","year":"2023","unstructured":"Kristensen LE, Strober B, Poddubnyy D, et al.. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Ther Adv Musculoskelet Dis. 2023, 15:1759720X221149965. 10.1177\/1759720X221149965","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor PC","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al.. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017, 376:652-62. 10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/374768-multivessel-coronary-artery-disease-in-a-patient-treated-with-tofacitinib-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:45:59Z","timestamp":1750189559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/374768-multivessel-coronary-artery-disease-in-a-patient-treated-with-tofacitinib-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.86235","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}